During cancer progression, BRCA1 mutant cancer cells gradually become reliant on high ELF3 expression to preserve a certain degree of genomic stability, making ELF3 a promising therapeutic target and biomarker in BRCA1-associated breast cancers. This evidence concerns the gene BRCA1 and breast carcinoma.